

Product specification: Cladribine pre-filled syringes	
Name of product	Cladribine injection. Aseptically prepared from licensed sterile starting materials.
Concentration	Concentration 2mg/ml in pre-filled syringes
Diluent	None
Volume	Dose specific volumes in accordance with the national dose banding tables with a maximum volume of 2ml in a single syringe
Final container	Polypropylene or polycarbonate sterile luer lock syringe, graduated in millilitres and sealed with sterile syringe cap/hub. Syringe and syringe cap/hub integrity to be validated. The validation should conform to the Protocols for the integrity testing of syringes published by the NHS Pharmaceutical QA Committee (2nd Edition, April 2013). Air bubbles within the final product must be minimised so the end user can use without need to remove air.
Starting materials	Licensed Cladribine (Litak®) 2mg/ml solution for injection CE marked sterile syringes and syringe caps/hubs
Labelling	Labelling must be compliant with the principles of labelling for safety and the BP General specification on unlicensed medicines. Tall Man lettering must be used for the drug name. NB: The brand name must be included on the label to distinguish from the infusion product.
Label sample	An example label is provided below stating the minimum requirements only (the label format is not restrictive and suppliers can use their preferred layout):-
	cLADribine (Litak®) xxmg in xxml For Subcutaneous Injection Check the solution is free from particles before administering
	Store in a Refrigerator at 2-8°C Protect From Light Expiry: dd/mm/yyyy BN: XXXXXXXXX Keep out of the reach and sight of children
	Manufacturer's details MS XXXXXX Caution Cytotoxic: Handle with care
Batch Number	All products will have a unique batch identification number
Latex status of - components - manufacturing process	All materials and manufacturing processes will be latex free or clearly labelled if not.
Stability	Stability studies should conform to the Standard Protocol for deriving and assessment of stability of Aseptic preparations (small molecules) published by the NHS Pharmaceutical QA Committee (4th Edition, April 2017).